P. Andrew

发表

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Allan C. deCamp, J. Mullins, J. Kublin, 2021, The New England journal of medicine.

Effi cacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission ( HPTN 046 ) : a randomised , double-blind , placebo-controlled trial

W. Fawzi, D. Moodley, L. Mofenson, 2011 .

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Allan C. deCamp, J. Kublin, J. Mascola, 2017, Statistical communications in infectious diseases.

Mucosal effects of tenofovir 1% gel

James Y. Dai, Ross D. Cranston, R. Gottardo, 2014, bioRxiv.

double blind, randomised, comparative trial asthma exacerbation in adults: one year, against salmeterol and fluticasone in protecting Montelukast and fluticasone compared with

H. Bisgaard, J. Bousquet, T. Haahtela, 2005 .

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

HPTN 068: A Randomized Control Trial of a Conditional Cash Transfer to Reduce HIV Infection in Young Women in South Africa—Study Design and Baseline Results

S. Tollman, O. Laeyendecker, J. Hughes, 2016, AIDS and Behavior.

The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women.

D. Moodley, H. McShane, H. Coovadia, 2014, Journal of acquired immune deficiency syndromes.

Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)

I. Frank, C. Hendrix, M. Marzinke, 2022, AIDS and Behavior.

Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody

Allan C. deCamp, J. Mascola, P. Gilbert, 2021, Journal of acquired immune deficiency syndromes.

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women

I. Frank, K. Mayer, C. Hendrix, 2017, Annals of Internal Medicine.

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

I. Frank, K. Mayer, C. Hendrix, 2016, The Journal of infectious diseases.

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Lindsay N. Carpp, Allan C. deCamp, J. Mullins, 2022, Nature Medicine.

A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)

James Y. Dai, Ross D. Cranston, A. Carballo-Diéguez, 2013, PloS one.

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

P. Kaleebu, N. Jones, M. Fowler, 2014, Journal of acquired immune deficiency syndromes.

EXTENDED PROPHYLAXIS WITH NEVIRAPINE DOES NOT AFFECT GROWTH IN HIV-EXPOSED INFANTS.

W. Fawzi, H. Coovadia, M. Fowler, 2019, Journal of acquired immune deficiency syndromes.

The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial.

S. Tollman, O. Laeyendecker, J. Hughes, 2016, The Lancet. Global health.

Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial

W. Fawzi, D. Moodley, L. Mofenson, 2012, The Lancet.

Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIV-Exposed Infants in Uganda: Results From the First HIV Vaccine Trial in Infants in Africa

S. Gurunathan, M. Fowler, P. Musoke, 2013, Journal of acquired immune deficiency syndromes.

Efficacy and Safety of an Extended Nevirapine Regimen in Infants of Breastfeeding Mothers With HIV-1 Infection for Prevention of HIV-1 Transmission (HPTN 046): 18-Month Results of a Randomized, Double-Blind, Placebo-Controlled Trial

W. Fawzi, D. Moodley, L. Mofenson, 2014, Journal of acquired immune deficiency syndromes.

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Lindsay N. Carpp, Allan C. deCamp, J. Mascola, 2021, EBioMedicine.

The eff ect of a conditional cash transfer on HIV incidence in young women in rural South Africa ( HPTN 068 ) : a phase 3 , randomised controlled trial

S. Tollman, O. Laeyendecker, J. Hughes, 2016 .

Author response: Mucosal effects of tenofovir 1% gel

James Y. Dai, Ross D. Cranston, R. Gottardo, 2015 .

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

Lindsay N. Carpp, Allan C. deCamp, J. Mascola, 2021, Human vaccines & immunotherapeutics.

Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Lindsay N. Carpp, Allan C. deCamp, J. Mascola, 2020 .

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

Allan C. deCamp, J. Mullins, J. Weiner, 2023, EBioMedicine.

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

P. Kaleebu, N. Jones, M. Fowler, 2014, Journal of acquired immune deficiency syndromes.

Emerging trends in contraceptive use, transitions and preferences among female sex workers screened for an HIV prevention clinical trial in Kisumu, Kenya: a cross-sectional study

P. Andrew, Richard Ndivo, R. Lando, 2019, Gates Open Research.